Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
出版年份 2021 全文链接
标题
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade
作者
关键词
-
出版物
NATURE MEDICINE
Volume 27, Issue 8, Pages 1432-1441
出版商
Springer Science and Business Media LLC
发表日期
2021-07-09
DOI
10.1038/s41591-021-01406-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Integrating taxonomic, functional, and strain-level profiling of diverse microbial communities with bioBakery 3
- (2021) Francesco Beghini et al. eLife
- Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
- (2019) Elisabeth Perez-Ruiz et al. NATURE
- Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients
- (2019) Brandilyn A. Peters et al. Genome Medicine
- Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors
- (2019) Satya Das et al. Journal for ImmunoTherapy of Cancer
- The gut microbiota influences anticancer immunosurveillance and general health
- (2018) Bertrand Routy et al. Nature Reviews Clinical Oncology
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- TumGrowth: An open-access web tool for the statistical analysis of tumor growth curves
- (2018) David P. Enot et al. OncoImmunology
- Efficacy and Safety of Nivolumab Alone or in Combination With Ipilimumab in Patients With Mucosal Melanoma: A Pooled Analysis
- (2017) Sandra P. D’Angelo et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- (2017) Mario Sznol et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
- (2017) Hans J. Hammers et al. JOURNAL OF CLINICAL ONCOLOGY
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance
- (2017) Whijae Roh et al. Science Translational Medicine
- Metagenomic Shotgun Sequencing and Unbiased Metabolomic Profiling Identify Specific Human Gut Microbiota and Metabolites Associated with Immune Checkpoint Therapy Efficacy in Melanoma Patients
- (2017) Arthur E. Frankel et al. NEOPLASIA
- Immune Toxicities Elicted by CTLA-4 Blockade in Cancer Patients Are Associated with Early Diversification of the T-cell Repertoire
- (2016) David Y. Oh et al. CANCER RESEARCH
- Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
- (2016) Willy Hugo et al. CELL
- Inflammatory Marker Testing Identifies CD74 Expression in Melanoma Tumor Cells, and Its Expression Associates with Favorable Survival for Stage III Melanoma
- (2016) S. Ekmekcioglu et al. CLINICAL CANCER RESEARCH
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities
- (2016) Sumit K. Subudhi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- VSEARCH: a versatile open source tool for metagenomics
- (2016) Torbjørn Rognes et al. PeerJ
- Increased Gut Redox and Depletion of Anaerobic and Methanogenic Prokaryotes in Severe Acute Malnutrition
- (2016) Matthieu Million et al. Scientific Reports
- Glycans affect DNA extraction and induce substantial differences in gut metagenomic studies
- (2016) Emmanouil Angelakis et al. Scientific Reports
- Distinct Commensals Induce Interleukin-1β via NLRP3 Inflammasome in Inflammatory Monocytes to Promote Intestinal Inflammation in Response to Injury
- (2015) Sang-Uk Seo et al. IMMUNITY
- Cell Surface CD74–MIF Interactions Drive Melanoma Survival in Response to Interferon-γ
- (2015) Keiji Tanese et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
- (2015) E. M. Van Allen et al. SCIENCE
- Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
- (2015) M. Vetizou et al. SCIENCE
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Inference of high resolution HLA types using genome-wide RNA or DNA sequencing reads
- (2014) Yu Bai et al. BMC GENOMICS
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- UPARSE: highly accurate OTU sequences from microbial amplicon reads
- (2013) Robert C Edgar NATURE METHODS
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
- (2012) Marco Antonio Moro-Garcia et al. CURRENT GENOMICS
- A framework for human microbiome research
- (2012) NATURE
- Metagenomic microbial community profiling using unique clade-specific marker genes
- (2012) Nicola Segata et al. NATURE METHODS
- Chapter 12: Human Microbiome Analysis
- (2012) Xochitl C. Morgan et al. PLoS Computational Biology
- Application of quantitative real-time PCR for rapid identification of Bacteroides fragilis group and related organisms in human wound samples
- (2011) Jia Tong et al. ANAEROBE
- Metagenomic biomarker discovery and explanation
- (2011) Nicola Segata et al. GENOME BIOLOGY
- Search and clustering orders of magnitude faster than BLAST
- (2010) Robert C. Edgar BIOINFORMATICS
- QIIME allows analysis of high-throughput community sequencing data
- (2010) J Gregory Caporaso et al. NATURE METHODS
- PyNAST: a flexible tool for aligning sequences to a template alignment
- (2009) J. G. Caporaso et al. BIOINFORMATICS
- Comparative assessment of human and farm animal faecal microbiota using real-time quantitative PCR
- (2009) Jean-Pierre Furet et al. FEMS MICROBIOLOGY ECOLOGY
- Decreased ERK and JNK signaling contribute to gene overexpression in “senescent” CD4+CD28- T cells through epigenetic mechanisms
- (2009) Yingxuan Chen et al. JOURNAL OF LEUKOCYTE BIOLOGY
- High Prevalence of Methanobrevibacter smithii and Methanosphaera stadtmanae Detected in the Human Gut Using an Improved DNA Detection Protocol
- (2009) Bédis Dridi et al. PLoS One
- Distribution of Different Species of the Bacteroides fragilis Group in Individuals with Japanese Cedar Pollinosis
- (2008) T. Odamaki et al. APPLIED AND ENVIRONMENTAL MICROBIOLOGY
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
- NetMHCpan, a method for MHC class I binding prediction beyond humans
- (2008) Ilka Hoof et al. IMMUNOGENETICS
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started